MY131126A - Sulfonamides - Google Patents

Sulfonamides

Info

Publication number
MY131126A
MY131126A MYPI95003923A MYPI9503923A MY131126A MY 131126 A MY131126 A MY 131126A MY PI95003923 A MYPI95003923 A MY PI95003923A MY PI9503923 A MYPI9503923 A MY PI9503923A MY 131126 A MY131126 A MY 131126A
Authority
MY
Malaysia
Prior art keywords
signifies
hydrogen
alkyl
signify
substituted
Prior art date
Application number
MYPI95003923A
Other languages
English (en)
Inventor
Volker Breu
Kaspar Burri
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loffler
Marcel Muller
Werner Neidhart
Henri Ramuz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY131126A publication Critical patent/MY131126A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Lubricants (AREA)
  • Surgical Instruments (AREA)
MYPI95003923A 1994-12-20 1995-12-18 Sulfonamides MY131126A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH383794 1994-12-20
CH241995 1995-08-24

Publications (1)

Publication Number Publication Date
MY131126A true MY131126A (en) 2007-07-31

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI95003923A MY131126A (en) 1994-12-20 1995-12-18 Sulfonamides

Country Status (25)

Country Link
US (1) US6004965A (enExample)
EP (1) EP0799209B1 (enExample)
JP (1) JP2989014B2 (enExample)
KR (1) KR100445085B1 (enExample)
CN (1) CN1098254C (enExample)
AT (1) ATE246681T1 (enExample)
AU (1) AU701767B2 (enExample)
BR (1) BR9510104A (enExample)
CA (1) CA2208018C (enExample)
CY (1) CY2495B1 (enExample)
CZ (1) CZ287916B6 (enExample)
DE (1) DE69531457T2 (enExample)
DK (1) DK0799209T3 (enExample)
ES (1) ES2203649T3 (enExample)
FI (1) FI120397B (enExample)
HU (1) HU228619B1 (enExample)
IL (1) IL116385A (enExample)
MA (1) MA23744A1 (enExample)
MY (1) MY131126A (enExample)
NO (1) NO316645B1 (enExample)
NZ (1) NZ297797A (enExample)
PT (1) PT799209E (enExample)
SA (1) SA95160421B1 (enExample)
TW (1) TW313568B (enExample)
WO (1) WO1996019459A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
DE69824090T2 (de) * 1997-08-19 2005-07-07 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von 2,5-disubstituierter Pyridine
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DK0979822T3 (da) * 1998-08-10 2006-03-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2-carbamoyl-pyridiner
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
US6596719B1 (en) * 1999-09-03 2003-07-22 Actelio Pharmaceuticals Ltd. 6 alkoxy-4-pyrimidinyl bis-sulfonamides
WO2001046156A1 (en) * 1999-12-22 2001-06-28 Actelion Pharmaceuticals Ltd. Butyne diol derivatives
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CN100379730C (zh) 2002-12-02 2008-04-09 埃科特莱茵药品有限公司 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP5042311B2 (ja) 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
NZ579107A (en) 2007-02-19 2012-05-25 Marinepolymer Tech Inc Poly-beta-1-4-n-acetylglucosamine hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
HRP20120476T1 (hr) 2007-11-05 2012-06-30 Novartis Ag Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza
PL2229356T3 (pl) 2007-12-03 2012-03-30 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
KR101338555B1 (ko) 2009-05-15 2013-12-09 노파르티스 아게 알도스테론 신타제 억제제로서의 아릴 피리딘
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
NZ602909A (en) 2010-04-15 2015-01-30 Marinepolymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
RU2013123793A (ru) 2010-11-24 2014-12-27 Лексикон Фармасьютикалз, Инк. Антитела, связывающиеся с notum пектинацетилэстеразой
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
HRP20180958T1 (hr) 2013-02-14 2018-07-27 Novartis Ag Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu)
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
US9931372B2 (en) 2015-01-23 2018-04-03 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
US12534449B2 (en) 2020-11-05 2026-01-27 Idorsia Pharmaceuticals Ltd Stable crystalline hydrate of clazosentan disodium salt
AU2022416870A1 (en) 2021-12-17 2024-06-27 Nxera Pharma Co., Ltd. Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
US20250228835A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines and related compounds and their use in treating medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (enExample) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (enExample) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL116385A (en) 2000-07-16
WO1996019459A1 (en) 1996-06-27
JP2989014B2 (ja) 1999-12-13
SA95160421B1 (ar) 2006-05-01
CN1170407A (zh) 1998-01-14
US6004965A (en) 1999-12-21
HK1001973A1 (en) 1998-07-24
MA23744A1 (fr) 1996-07-01
FI120397B (fi) 2009-10-15
DE69531457T2 (de) 2004-06-24
EP0799209B1 (en) 2003-08-06
NO316645B1 (no) 2004-03-22
CZ187497A3 (en) 1997-10-15
CZ287916B6 (cs) 2001-03-14
FI972628A0 (fi) 1997-06-18
NO972538L (no) 1997-06-04
NZ297797A (en) 1999-10-28
PT799209E (pt) 2003-12-31
KR100445085B1 (ko) 2004-10-14
TW313568B (enExample) 1997-08-21
MX9704587A (es) 1998-07-31
CN1098254C (zh) 2003-01-08
NO972538D0 (no) 1997-06-04
HU228619B1 (en) 2013-04-29
ES2203649T3 (es) 2004-04-16
EP0799209A1 (en) 1997-10-08
CA2208018C (en) 2007-03-27
CY2495B1 (en) 2005-09-02
JPH10509182A (ja) 1998-09-08
FI972628L (fi) 1997-06-18
BR9510104A (pt) 1997-11-25
HUT77884A (hu) 1998-09-28
CA2208018A1 (en) 1996-06-27
IL116385A0 (en) 1996-03-31
AU701767B2 (en) 1999-02-04
DK0799209T3 (da) 2003-11-24
AU4304196A (en) 1996-07-10
DE69531457D1 (en) 2003-09-11
ATE246681T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
MY131126A (en) Sulfonamides
GB9514473D0 (en) Chemical compounds
WO1994013658A3 (en) Benzocycloheptenes, benzoxepines and benzothiepines
NO970162L (no) Substituerte pyrimidinforbindelser og anvendelse derav
AU566758B2 (en) 1,3,4,5-tetra hydrobenz(c,d) indoles
ES2162825T3 (es) Derivados de piperazina.
MXPA03002911A (es) Compuestos quimicos.
MXPA02012659A (es) Derivados de pirazindiona condensados.
BG104447A (en) Biphenylamidine derivatives
AU1170300A (en) Indole derivatives and their use as serotonin receptor ligands
WO2003004497A1 (en) Novel heterocyclic compound
IE892994L (en) Novel pyridyl- and pyrimidyl derivatives
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2002213419A1 (en) Condensed pyridoindole derivatives
MY103172A (en) Tricyclic pyridine derivatives.
MY131381A (en) Piperazine derivatives suitable for use as pharmaceuticals, in particular as 5-ht1a receptor binding agents.
TW351718B (en) Acylated aminoalkanimidazoles and -triazoles
MXPA02012472A (es) Compuestos quimicos.
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
MD1744F2 (ro) Săruri ale acidului clavulanic şi procedeu de obţinere a lor
AP2001002045A0 (en) FKBP inhibitors.
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
AU560621B2 (en) Polymethylene imine substituted triazines
HU9302196D0 (en) New sulphonyl-urea derivatives
EP0846465A4 (en) Remedy for anxiety neurosis